Mr James Foster is a co-founder of Virax Biolabs Group Limited (Nasdaq: VRAX) and serves as its Chairman, Chief Executive Officer and a member of the Board of Directors. He founded the business in 2013 and has led its evolution into a cross-regional biotechnology platform with operations in the UK, Europe and Asia, focused on next-generation T cell immunodiagnostics, moving beyond pathogen detection towards the measurement of T cell–mediated immunity. He has overseen its listing on Nasdaq and subsequent financings.
Under his leadership, the company is developing ViraxImmune™, a proprietary, virus-agnostic T cell immune-profiling platform designed to measure and monitor immune responses across multiple pathogens. Its initial clinical priority is Long COVID, as part of a broader focus on post-acute infection syndromes and immune-mediated disease, with an ambition to build a scalable immune-profiling platform spanning infectious disease, vaccine response monitoring and immune health. Virax is building a pipeline from research-use-only (RUO) products and preclinical immunology services—including its ImmuneSelect portfolio of assays—through to future clinical deployment supported by ongoing clinical and regulatory work.
Prior to founding the business, Mr Foster built his career in capital markets, beginning in London with the Royal Bank of Canada and NEX Group (formerly ICAP) before co-founding Emerging Asia Capital. He holds a BA (Hons) from the University of Nottingham and an MSc from SOAS, University of London.
